Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 98-102

  Quella, Susan K ^b   Loprinzi, Charles L ^a   Sloan, Jeff ^b   Novotny, Paul ^b   Perez, Edith A ^b   Burch, Patrick A ^b   Antolak Jr , Stanley J ^b   Pisansky, Thomas M ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Hot flashes; Prostate; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; CLONIDINE; GONADORELIN DERIVATIVE; MEGESTROL ACETATE; VENLAFAXINE;

ADULT; AFFECTIVE NEUROSIS; AGED; ANOREXIA; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; FATIGUE; HOT FLUSH; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SLEEP DISORDER; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 0032861507     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00024     Document Type: Article

References (15)

1. Charig, C. R. and Rundle, J. S.: Flushing: long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology, 33: 175, 1989.
2. Steinfeld, A. D. and Reinhardt, C.: Male climacteric after orchiectomy in patient with prostatic cancer. Urology, 16: 620, 1980.
3. Ginsburg, J. and O'Reilly, B.: Climacteric flushing in a man. Brit. Med. J., 287: 262, 1983.
4. Quella, S. K., Loprinzi, C. L. and Dose, A. M.: A qualitative approach to defining ̈hot flashes̈ in men. Urol. Nurs., 14: 155, 1994.
5. Loprinzi, C. L., Goldberg, R. M., O'Fallon, J. R., Quella, S. K., Miser, A. W., Mynderse, L. A., Brown, L. D., Tschetter, L. K., Wilwerding, M. B., Dose, A. M. and Oesterling, J. E.: Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J. Urol., 151: 634, 1994.
6. Atala, A., Amin, M. and Harty, J. I.: Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology, 39: 108, 1992.
7. Loprinzi, C. L., Michalak, J. C., Quella, S. K., O'Fallon, J. R., Hatfield, A. K., Nelimark, R. A., Dose, A. M., Fischer, T., Johnson, C. and Klatt, N. E.: Megestrol acetate for the prevention of hot flashes. New Engl. J. Med., 331: 347, 1994.
8. Dawson, N. A. and McLeod, D. G.: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate of cancer: expansion of the antiandrogen withdrawal syndrome. J. Urol., 153: 1946, 1995.
9. Wehbe, T. W., Stein, B. S. and Akerley, W. L.: Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin. Proc., 72: 932, 1997.
10. Quella, S. K., Loprinzi, C. L., Sloan, J. A., Vaught, N. L., DeKrey, W. L., Fischer, T., Finck, G., Pierson, N. and Pisansky, T. M.: Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer, 82: 1784, 1998.
11. Cunningham, L. A.: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann. Clin. Psychiatr., 9: 157, 1997.
12. Loprinzi, C. L., Pisansky, T. M., Fonseca, R., Sloan, J. A., Zahasky, K. M., Quella, S. K., Novotny, P. J., Rummans, T. A., Dumesic, D. A. and Perez, E. A.: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J. Clin. Oncol., 16: 2377, 1998.
13. Conover, W. J.: Practical Nonparametric Statistics. New York: John Wiley and Sons, pp. 127-130, 1971.
14. Fava, M., Mulroy, R. M. and Alpert, J.: Emergency of adverse events following discontinuation of treatment with extended-release venlafaxine. Amer. J. Psychiatr., 154: 1760, 1997.
15. Eaton, A. C. and McGuire, N.: Cyproterone acetate in treatment of post-orchiectomy hot flushes. Double-blind cross-over trial. Lancet, 2: 1336, 1983.